Literature DB >> 26698850

Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.

L Dreyer1, M Magyari2, B Laursen3, R Cordtz1, F Sellebjerg4, H Locht5.   

Abstract

Entities:  

Keywords:  Ankylosing Spondylitis; Anti-TNF; Rheumatoid Arthritis

Mesh：

Substances：

Year:  2015        PMID： 26698850     DOI： 10.1136/annrheumdis-2015-208490

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

1.  Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study.

Authors:  Mandakh Bekhbat; Zhihao Li; Namrataa D Mehta; Michael T Treadway; Michael J Lucido; Bobbi J Woolwine; Ebrahim Haroon; Andrew H Miller; Jennifer C Felger
Journal:  Mol Psychiatry       Date:  2022-08-04       Impact factor: 13.437

2.  Anti-TNF therapy for inflammatory bowel disease in patients with neurodegenerative Niemann-Pick disease Type C.

Authors:  Isabelle Williams; Sumeet Pandey; Wolfram Haller; Hien Quoc Huynh; Alicia Chan; Gesche Düeker; Ruth Bettels; Laurent Peyrin-Biroulet; Chinenye R Dike; Catherine DeGeeter; David Smith; Nada Al Eisa; Nick Platt; Thorsten Marquardt; Tobias Schwerd; Frances M Platt; Holm H Uhlig
Journal:  Wellcome Open Res       Date:  2022-01-11

3.  Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis.

Authors:  Delamo I Bekele; Elizabeth Cheng; Andreas Reimold; Christian Geier; Kavya Ganuthula; Jessica A Walsh; Daniel O Clegg; Maureen Dubreuil; Prashant Kaushik; Bernard Ng; Elizabeth Chang; Ryan Duong; Jina Park; Gail S Kerr
Journal:  Rheumatol Int       Date:  2021-11-01       Impact factor: 3.580

Review 4.  Inflammation as a Pathophysiologic Pathway to Anhedonia: Mechanisms and Therapeutic Implications.

Authors:  Mandakh Bekhbat; Michael T Treadway; Jennifer C Felger
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 5.  Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example.

Authors:  Katerina Chatzidionysiou; Merete Lund Hetland; Thomas Frisell; Daniela Di Giuseppe; Karin Hellgren; Bente Glintborg; Dan Nordström; Kalle Aaltonen; Minna Rk Törmänen; Eirik Klami Kristianslund; Tore K Kvien; Sella A Provan; Bjorn Björn Guðbjörnsson; Lene Dreyer; Lars Erik Kristensen; Tanja Schjødt Jørgensen; Lennart Jacobsson; Johan Askling
Journal:  RMD Open       Date:  2018-04-12

6.  Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events.

Authors:  Amy Kunchok; Allen J Aksamit; John M Davis; Orhun H Kantarci; B Mark Keegan; Sean J Pittock; Brian G Weinshenker; Andrew McKeon
Journal:  JAMA Neurol       Date:  2020-08-01       Impact factor: 18.302

7.  Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis.

Authors:  Jordi Gratacós; Caridad Pontes; Xavier Juanola; Jesús Sanz; Ferran Torres; Cristina Avendaño; Antoni Vallano; Gonzalo Calvo; Eugenio de Miguel; Raimon Sanmartí
Journal:  Arthritis Res Ther       Date:  2019-01-08       Impact factor: 5.156

8.  Improved Glucocorticoid Receptor Ligands: Fantastic Beasts, but How to Find Them?

Authors:  Laura Van Moortel; Kris Gevaert; Karolien De Bosscher
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-24       Impact factor: 5.555

Review 9.  Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review.

Authors:  Akshitha Thatiparthi; Amylee Martin; Jeffrey Liu; Alexander Egeberg; Jashin J Wu
Journal:  Am J Clin Dermatol       Date:  2021-04-16       Impact factor: 7.403

Review 10.  Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system.

Authors:  Elsa How Shing Koy; Pierre Labauge; Athan Baillet; Clément Prati; Hubert Marotte; Yves-Marie Pers
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-07-09       Impact factor: 5.346
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.